Skip to content

The metabonomics study of breast and prostatic malignant tumor

The metabonomics study of breast and prostatic malignant tumor

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040091
Enrollment
Unknown
Registered
2020-11-20
Start date
2020-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human breast cancer and prostate cancer tumor micro-environment

Interventions

Case series:Single-cell sequencing, bulk RNAseq, proteomics, and imaging histology of tumor micro-environments

Sponsors

Affiliated Sixth People's Hospital, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients voluntarily participate in this study, sign the informed consent, good compliance, with follow-up; 2. Pathologically diagnosed breast and prostate cancer, imaging indicates bone metastasis, bone puncture pathology testing is required to clarify bone metastasis;

Exclusion criteria

Exclusion criteria: Patients with breast and prostate cancer who refuse to have bone punctures.

Design outcomes

Primary

MeasureTime frame
Progression Free Survival, PFS;Security;

Secondary

MeasureTime frame
Overall Survival, OS;Objective Response Rate, ORR;Duration of Response, DOR;Disease Control Rate, DCR;

Countries

China

Contacts

Public ContactHu Haiyan

Affiliated Sixth People's Hospital, Shanghai Jiaotong University

xuri1104@163.com+86 18930174575

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026